Impact of guselkumab on fatigue and mediation analysis of independent treatment effect of guselkumab on fatigue in patients with active psoriatic arthritis: Results from DISCOVER-1&2

被引：0
|
作者：
Rahman, Proton [1 ]
Helliwell, Philip S. [2 ]
Deodhar, Atul [3 ]
Kollmeier, Alexa P. [4 ]
Hsia, Elizabeth [4 ,5 ]
Zhou, Bei [4 ]
Lin, Xiwu [4 ]
Han, Chenglong [4 ]
Yang, Ya-Wen [4 ]
Mease, Philip J. [6 ]
机构：
[1] Mem Univ Newfoundland, St John, NF, Canada
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Janssen Res & Dev LLC, Raritan, NJ USA
[5] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[6] Univ Washington, Swedish Med Ctr, Prov St Joseph Hlth, Seattle, WA 98195 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27594
引用
收藏
页码：AB153 / AB153
页数：1
相关论文
共 50 条
  • [31] Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2
    Gottlieb, Alice B.
    Merola, Joseph F.
    Armstrong, April W.
    Savage, Laura
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Zhou, Bei
    Yang, Ya-Wen
    Sweet, Kristen
    Boehncke, Wolf-Henning
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB39 - AB39
  • [32] AN ANALYSIS OF FATIGUE IN PATIENTS WITH PSORIATIC DISEASE UTILIZING SF-36 VITALITY SCORES: RESULTS THROUGH WEEK 24 IN PHASE 3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
    Merola, J. F.
    Liu, Y. H.
    Yang, Y. W.
    Miller, M.
    Shawi, M.
    Chan, D.
    Khattri, S.
    Savage, L.
    Boehncke, W. H.
    Han, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1573 - 1574
  • [33] GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY
    Rahman, P.
    Mcinnes, I.
    Deodhar, A.
    Schett, G.
    Mease, P. J.
    Shawi, M.
    Cua, D.
    Sherlock, J.
    Kollmeier, A.
    Xu, X. L.
    Jiang, Y.
    Sheng, S.
    Ritchlin, C. T.
    Mcgonagle, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 826 - 827
  • [34] An analysis of fatigue in patients with psoriatic disease utilizing SF-36 vitality scores: Results through week 24 in phase 3 trials of guselkumab in patients with psoriasis and psoriatic arthritis
    Merola, Joseph F.
    Liu, Yi-Hsuan
    Yang, Ya-Wen
    Miller, Megan
    Shawi, May
    Chan, Daphne
    Khattri, Saakshi
    Savage, Laura
    Boehncke, Wolf-Henning
    Han, Chenglong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB137 - AB137
  • [35] Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis
    Rahman, Proton
    Ritchlin, Christopher T.
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    Mease, Philip J.
    Gottlieb, Alice B.
    Kafka, Shelly
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Shawi, May
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Ramachandran, Paraneedharan
    Zhuang, Yanli
    McInnes, Iain B.
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (12) : 1815 - 1823
  • [36] GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 2 YEARS OF DISCOVER-2
    Curtis, J.
    McInnes, I.
    Rahman, P.
    Gladman, D. D.
    Yang, F.
    Peterson, S.
    Kollmeier, A.
    Shiff, N.
    Han, C.
    Shawi, M.
    Tillett, W.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1563 - 1564
  • [37] Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
    Curtis, Jeffrey
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna
    Yang, Feifei
    Peterson, Steve
    Kollmeier, Alexa
    Shiff, Natalie
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3651 - 3653
  • [38] Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub- Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naive Patients
    Gladman, Dafna
    Baraliakos, Xenofon
    Starr, Michael
    Ranza, Roberto
    Rampakakis, Emmanouil
    Shiff, Natalie
    Nantel, Francois
    Han, Chenglong
    Ostor, Andrew James Knowles
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2796 - 2798
  • [39] Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
    Rahman, Proton
    McInnes, Iain
    Deodhar, Atul
    Schett, Georg
    Mease, Philip
    Shawi, May
    Cua, Daniel
    Sherlock, Jonathan
    Kollmeier, Alexa
    Xu, Xie
    Jiang, Yusang
    Sheng, Shihong
    Ritchlin, Christopher
    McGonagle, Dennis
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2757 - 2760
  • [40] In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
    Rahman, Proton
    Helliwell, Philip
    Deodhar, Atul
    Kollmeier, Alexa
    Hsia, Elizabeth
    Zhou, Bei
    Lin, Xiwu
    Han, Chenglong
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345